ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations
ProQR Therapeutics (NASDAQ:PRQR) Second Quarter 2025 Results
Key Financial Results
Revenue: €3.98m (down 39% from 2Q 2024).
Net loss: €12.2m (loss widened by 352% from 2Q 2024).
€0.12 loss per share (further deteriorated from €0.033 loss in 2Q 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
ProQR Therapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 50%.
Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 4.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for ProQR Therapeutics that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Software firm Sapiens to be acquired by Advent for $2.5 billion
(Reuters) -Israeli software company Sapiens International said on Wednesday that it will be acquired by private equity firm Advent for $2.5 billion in cash. Sapiens' shareholders will receive $43.50 per share in cash, a premium of about 47.5% over its last close of $29.50 on the Nasdaq on Tuesday. Sapiens will become a privately held company after the deal is completed, the company said. It offers software solutions to the insurance sector. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Veritone Inc (VERI) Q2 2025 Earnings Call Highlights: Strong Software Growth Amidst Managed ...
Revenue: Over $24 million for Q2 2025, flat compared to Q2 2024. Software Products and Services Growth: Over 45% year-over-year, excluding Veritone Hire. Public Sector Revenue Growth: Over 90% year-over-year. Commercial Enterprise Revenue Growth: Improved by $0.8 million year-over-year. Managed Services Decline: $1.9 million decrease, driven by a decline in representation services. Gross Profit: $15.3 million, down from $16.4 million in Q2 2024. GAAP Gross Margin: 63.9%, compared to 68.2% in Q2 2024. Operating Loss: $19.3 million, improved by 5% year-over-year. Net Loss from Continuing Operations: $26.8 million, increased by 14.5% year-over-year. Non-GAAP Net Loss: $8.7 million, improved from $9.7 million in Q2 2024. Cash and Restricted Cash: $13.9 million as of June 30, 2025. Debt: Approximately $128 million, down from $201 million in December 2021. Q3 2025 Revenue Guidance: Expected between $28 million and $30 million. Fiscal 2025 Revenue Guidance: Expected between $108 million and $115 million. Warning! GuruFocus has detected 5 Warning Signs with VERI. Release Date: August 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Veritone Inc (NASDAQ:VERI) reported revenue of over $24 million for the quarter, reaching the high end of their updated guidance. The company experienced strong organic non-Veritone hire software revenue growth of over 45% in the quarter. Veritone Inc (NASDAQ:VERI) secured 104 new software customers and grew their Veritone Data Refinery (VDR) pipeline by over 100% from Q1. The public sector pipeline increased to $189 million, up from $110 million at the end of the first quarter. The company announced cost-saving initiatives expected to generate $10 million in annualized savings, strengthening their financial position. Negative Points Managed services revenue declined by $1.9 million, driven by a decrease in representation services. GAAP gross profit decreased by $1.1 million, with gross margins declining from 68.2% to 63.9%. Net loss from continuing operations increased by $3.4 million or 14.5% compared to Q2 2024. The company experienced a decline in total software product and service customers by 9% year-over-year. Veritone Inc (NASDAQ:VERI) anticipates continued negative trends in representation services throughout 2025. Q & A Highlights Q: Can you elaborate on what needs to convert to support the step-up in acceleration for the top line, and what gives you confidence in this visibility? A: Ryan Steelberg, CEO, explained that they have the smallest gap of "go get" revenue to realize their Q3 guidance. Much of the revenue is already contracted or in process, such as with the Department of Defense (DoD) contracts and new customers with Veritone Data Refinery (VDR). They are confident in their ability to meet guidance due to existing customer transactions and ongoing revenue generation. Q: How does Veritone differentiate itself in regulated industries like defense and law enforcement compared to other AI platforms? A: Ryan Steelberg highlighted that Veritone's aiWARE platform is model-agnostic and can manage the full end-to-end stack, allowing customers to rely on Veritone as models mature. Veritone's ability to process unstructured data at scale, such as audio and video, is a significant differentiator. The platform's flexibility to operate in various environments, including air-gapped and on-premises, further sets it apart. Q: Regarding the Air Force contract, do you need to close more deals of this size to meet your guidance, and how does this contract impact future opportunities? A: Ryan Steelberg stated that the Air Force contract is a significant opportunity that will likely lead to further expansion within the DoD and other agencies. The contract itself presents a substantial growth opportunity, and Veritone has a healthy pipeline that supports their guidance. The visibility and credibility from this contract are expected to facilitate additional opportunities. Q: Can you provide more details on the $20 million VDR pipeline and its translation to revenue? A: Ryan Steelberg explained that the $20 million pipeline is qualified with high visibility over the next 3 to 12 months. VDR has found a strong product-market fit, particularly with hyperscalers and AI model developers. The demand for high-quality training data is significant, and Veritone is well-positioned to capitalize on this opportunity. Q: The full-year guidance was raised, but the non-GAAP net loss was also adjusted. Can you explain the reasons behind this? A: Michael Zemetra, CFO, clarified that the adjustment in non-GAAP net loss is due to margin compression from the rapid growth of VDR. While revenue guidance was raised, the margins on VDR are currently compressed, impacting the net loss forecast. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Mizuho Raises PT on ICON Public Limited Company (ICLR) to $225; Maintains ‘Outperform' Rating
With a low price-to-earnings multiple and a significant presence in Seth Klarman's investment portfolio, ICON Public Limited Company (NASDAQ:ICLR) earns a spot on our list of the 12 Cheap Value Stocks to Buy Now According to Seth Klarman. A close-up of a clinical trial data report, symbolizing the company's commitment to evidence-based medicine. On July 25, 2025, Mizuho raised its price target on ICON Public Limited Company (NASDAQ:ICLR) from $173 to $225, maintaining an 'Outperform' rating. The price revision is attributed to the company's stronger-than-expected operational metrics. Eliminating earlier fears of a slowdown, its quarterly booking trends remained stable. Furthermore, improved cancellation rates and easing trial delays boosted confidence in the company's execution. Moreover, the analyst feels enhanced earnings visibility for 2026 for ICON Public Limited Company (NASDAQ:ICLR), indicating a stronger growth trajectory, in spite of macro uncertainties in the clinical research market. Thus, the analyst's price revision reflects both the short-term momentum and long-term strategic positioning, increasing the possibility of the company capturing a larger share of clinical trial demand in the coming years. ICON Public Limited Company (NASDAQ:ICLR) executes clinical research globally, offering outsourced development and commercialization services. It is included in our list of cheap value stocks to buy. While we acknowledge the potential of ICLR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
